Search company, investor...

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

Founded Year




Total Raised


Date of IPO


Market Cap


Stock Price


About Inotek Pharmaceuticals

Inotek Pharmaceuticals is a biotechnology company focused on the discovery and development of drugs to address serious diseases of the eye. Inotek scientists have identified a deep pipeline of drug candidates to ameliorate inflammation, ischemia-reperfusion injury, and oxidative stress, which are key targets for drugs to treat Glaucoma, Ocular Hypertension, Age-related Macular Degeneration and Retinal Neuropathies. The Company's lead program, trabodenoson (INO-8875) is a highly selective adenosine mimetic that targets the A1 sub-receptor. Trabodenoson brings a novel and elegant mechanism of action for the treatment of elevated intraocular pressure (IOP) associated with open-angle glaucoma and ocular hypertension. This new approach to lowering IOP augments the natural process that healthy eyes use to allow excess fluid to drain from the eye through the trabecular meshwork, and makes trabodenoson, if ultimately approved by health authorities worldwide, a valuable tool that ophthalmologist can use alone or in conjunction with any of the available medicines for glaucoma. The candidate has completed a Phase 1 and Phase2 clinical trials in patients and is currently being evaluated in a multiple-dose late Phase 2 trial. In the completed clinical trials, trabodenoson was well tolerated and was shown to significantly reduce intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Inotek Pharmaceuticals Headquarters Location

91 Hartwell Avenue 2nd Floor

Lexington, Massachusetts, 02421,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Inotek Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inotek Pharmaceuticals is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

838 items

Inotek Pharmaceuticals Patents

Inotek Pharmaceuticals has filed 22 patents.

patents chart

Application Date

Grant Date


Related Topics




Purines, Nucleotides, Thioesters of coenzyme A, Nucleosides, Adenosine receptor agonists


Application Date


Grant Date



Related Topics

Purines, Nucleotides, Thioesters of coenzyme A, Nucleosides, Adenosine receptor agonists



Inotek Pharmaceuticals Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Inotek Pharmaceuticals Rank

  • When was Inotek Pharmaceuticals founded?

    Inotek Pharmaceuticals was founded in 1996.

  • Where is Inotek Pharmaceuticals's headquarters?

    Inotek Pharmaceuticals's headquarters is located at 91 Hartwell Avenue, Lexington.

  • What is Inotek Pharmaceuticals's latest funding round?

    Inotek Pharmaceuticals's latest funding round is IPO.

  • How much did Inotek Pharmaceuticals raise?

    Inotek Pharmaceuticals raised a total of $143.9M.

  • Who are the investors of Inotek Pharmaceuticals?

    Investors of Inotek Pharmaceuticals include MedImmune Ventures, Rho Ventures, Care Capital, Pitango Venture Capital, Devon Park Bioventures and 9 more.

  • Who are Inotek Pharmaceuticals's competitors?

    Competitors of Inotek Pharmaceuticals include Entegrion, Armgo Pharma, Amplyx Pharmaceuticals, Cognate BioServices, InvivoSciences, Ra Pharmaceuticals, Curemark, Amnis Corporation, Biomatrica, CombiMatrix and 34 more.

You May Also Like

Solidus Biosciences Logo
Solidus Biosciences

Solidus Biosciences is a company that received a STTR Phase II grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their award is funded under the American Recovery and Reinvestment Act of 2009 and their project will address further development and commercialization of a multi-enzyme lead optimization chip (Multizyme Chip) for high-throughput generation of lead compound analogs coupled with cell-based screening for the rapid identification of biologically active derivatives. Such a capability directly impacts a key bottleneck in drug discovery; namely, the efficient optimization of lead compounds to develop drugs with optimal pharmacological properties. Solidus Biosciences, Inc. proposes to combine six biocatalysis with pharmacological screening to provide rapid identification of biologically active compounds against cell-specific targets, which is a new paradigm for lead optimization. Moreover, the Multizyme Chip platform will be well-suited for lead optimization in related industries, including agrochemicals, cosmetics, and cosmeceuticals. The Solidus technology will thus improve the competitiveness and efficiency of the pharmaceutical, cosmetics, and chemical industries, and will serve as a rich source of new and improved commercial products. The broader impacts of this research are the advances that Solidus Biosciences will achieve toward generating better and safer drugs, reducing the cost to develop these drugs, and increasing the overall efficiency of the pharmaceutical industry. Solidus will generate Multizyme Chips for purchase by pharmaceutical and biotechnology companies to facilitate their lead optimization programs, particularly those involving natural product-derived and complex synthetic small molecule leads. Cryopreservation techniques developed in Phase II will enable the sale of chips and chip-handling devices produced during Phase I, and will allow seamless penetration of the Solidus technology platform into the company's target markets. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: Development of a Lead Optimization Chip for Drug Discovery. Their research project aims to develop a new method for generating lead compounds by using enzymatic modification of compound sets. Availability of new methodology to generate biologically active compounds from existing molecules may enhance the success of the drug discovery process and may lead to the discovery of new and useful therapeutics. Solidus Biosciences is a company that received a STTR Phase I grant for a project entitled: High-Throughput RNAi Screening of Mammalian Cells. Their research project aims to develop a system for the rapid screening of siRNAs that can inhibit genes involved in cellular responses such as hyperosmotic stress that can affect pathways of high commercial importance, including protein production. Use of hyperosmotic stress as a proof of concept system will demonstrate the feasibility of high-throughput RNAi screening and will at the same time yield results that can be used to improve monoclonal antibody production in commercial and laboratory settings Production of biopharmaceuticals such as antibodies is exquisitely responsive to the culture conditions under which the cells are grown and thus can be improved through optimizing such settings, which in turn, would affect the genes involved in the specific synthetic pathways of interest. Development of a rapid methodology to identify inhibitory RNA molecules that can inhibit genes that adversely affect yield would be of significant importance to pharmaceutical companies that produce protein therapeutics and may result in a lowering of the const of these therapeutic entities.


NeuroGenomeX is a drug discovery company developing novel treatments for diseases of the brain and nervous system. The current NeuroGenomeX discovery program is focused on therapeutic target areas of epilepsy and traumatic brain injury. NeuroGenomeX is advancing its lead drug candidate, 2-deoxy-D-glucose (2DG), as an anticonvulsant that stops seizures and has beneficial effects against adverse long-term consequences of epilepsy. 2DG also has shown favorable therapeutic neuroprotective effects in animal models of traumatic brain injury (TBI).


eSionic, formerly Zettacore, enables devices and systems that consume less materials, generate less waste, have longer life, operate with higher reliability, use less energy, integrate seamlessly, operate more efficiently and cost less.

Paloma Pharmaceuticals

Paloma Pharmaceuticals, Inc. is a drug development company focusing on pathologies with a vascular component including cancer, ocular diseases (macular degeneration and diabetic retinopathy), arthritis, fibrotic diseases (pulmonary fibrosis) endometriosis, osteoporosis and skin diseases (psoriasis and atopic dermatitis). Paloma owns the intellectual property relating to a series of , small molecule drugs created through an integrated design platform incorporating , customized and industry standard computational tools that has therapeutic potential for the treatment of the foregoing diseases.

Gahaga Biosciences

Gahaga Biosciences was founded in 2006 to commercialize a method for the isolation of stem cells from placental and umbilical tissues to be used in basic research. Gahaga Biosciences intends to provide stem cells to the research and commercial markets which are valued as a potential source of a range of types of tissue. Many scientists say embryonic stem cells are generally more versatile than adult cells, although they continue to explore the possibilities of adult stem cells. The company believe that placental and umbilical stems cells are an ideal model system for conducting basic research on cell differentiation and regulation. Gahaga Biosciences seeks to supply researchers with materials to focus on the basic mechanisms of stem cell differentiation - how stem cells make the decision to move from their stem cell state into a more committed phenotype. Gahaga also seeks to exploit the company's experience in other methods such as pancreatic islets.

Salzburg Therapeutics

Salzburg Therapeutics is a drug development company that is developing Cytotoxamer and Genotoxamer products for cancer treatment. The company's technology aims to provide a solution for delivering activated forms of anticancer drugs, nanoparticles, and other moieties specifically to cancer cells.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.